DPP4 and heart failure: Therefore, while some DPP-4 inhibitors such as Saxagliptin may cause worsening of heart failure events, Sitagliptin, and particularly Linagliptin has significant clinical data available to suggest a good safety profile, albeit with no significant cardiovascular benefits.